ClinicalTrials.gg
CompletedNCT00040677Updated Jul 18, 2011

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

A Phase 2 interventional study of Low Dose ICA-17043 and High dose ICA-17043 in Sickle Cell Disease and Sickle Cell Anemia, sponsored by Icagen. Completed at 19 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2011-07-18.

Sponsored by Icagen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
121st of 559
90 · median 31
Started
2002
with 5 others
Phase 2
161 of 733
23 open now
Registered
21st of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 121st largest by enrollment of the 559 interventional ones that give a count, is one of 6 that started in 2002, is one of 161 in phase 2, and was the 21st registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and thus should prevent or delay the sickling process. By reducing sickled cells, an improvement in anemia, a reduction in painful crises, and ultimately, less end-organ disease is anticipated.

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia

Keywords

  • sickle cell anemia
  • sickle cell disease
  • anemia
  • ICA-17043
  • senicapoc
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous (HbSS) Sickle Cell Anemia
  • Otherwise healthy (based on medical history, physical examination, 12-lead , and clinical laboratory tests)
  • Patients may be receiving hydroxyurea, but must have been dose stabilized for at least 3 months
  • Patient has a history of at least one acute vaso-occlusive event requiring hospitalization

Exclusion criteria

Exclusion Criteria:

  • Patient participating in a chronic transfusion program
  • Patient having a total of \< 4.0 g/dL or > 10.0 g/dL
  • Patient having a HbA > 10%
  • Patient considering undergoing an elective surgery
  • Patient taking prohibited medications such as Epoetin, Warfarin, etc.
  • Patient who has had previous gastrointestinal surgery, except cholecystectomy or appendectomy
  • Patient with significant active cardiovascular, neurologic, endocrine, hepatic, or renal disorders unrelated to sickle cell anemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    ICA-17043 Low Dose 6 mg/day

    Active study medication: 100 mg loading dose; 6 mg maintenance dose per day

    Drug: Low Dose ICA-17043

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    ICA-17043 High Dose 10 mg/day

    Active study medication: 150 mg loading dose; 10 mg maintenance dose per day

    Drug: High dose ICA-17043

Interventions

  • Low dose arm

  • 150 mg Loading Dose; 10 mg daily dose

  • DrugPlacebo

    Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb)

    Time frame: 12 Weeks

Secondary outcomes

  1. Changes in other hematologic measurements

    Time frame: 12 weeks

  2. Changes in RBC indices, including: mean corpuscular volume (MCV), mean corpuscular Hb concentration (MCHC), and mean corpuscular Hb (MCH

    Time frame: 12 weeks

  3. Other laboratory measures associated with sickle cell crises activity including: direct and indirect bilirubin and lactic dehydrogenase (LDH)

    Time frame: 12 weeks

  4. Rate of painful crises

    Time frame: 12 weeks

  5. Time to first painful crisis

    Time frame: 12 weeks

  6. Morbidity of painful crises (maximum morbidity index, derived variable)

    Time frame: 12 weeks

  7. Pain intensity scores

    Time frame: 12 weeks

  8. Quality of Life (SF 36)

    Time frame: 12 Weeks

  9. Health economic data

    Time frame: 12 weeks

  10. Average plasma concentration

    Time frame: 12 weeks

  11. Correlation between the average plasma concentration and the change in Hb from Baseline to study endpoint

    Time frame: 12 weeks

07

Study locations

19 sites
  • Study Site
    Birmingham, Alabama, United States
  • Study Site
    Oakland, California, United States
  • Study Site
    San Francisco, California, United States
  • Study Site
    Washington, District of Columbia, United States
  • Study Site
    Augusta, Georgia, United States
  • Study Site
    Chicago, Illinois, United States
  • Study Site
    Baltimore, Maryland, United States
  • Study Site
    Boston, Massachusetts, United States
  • Study Site
    Detroit, Michigan, United States
  • Study Site
    Jackson, Mississippi, United States
  • Study Site
    Brooklyn, New York, United States
  • Study Site
    New York, New York, United States
  • Study Site
    Chapel Hill, North Carolina, United States
  • Study Site
    Durham, North Carolina, United States
  • Study Site
    Philadelphia, Pennsylvania, United States
  • Study Site
    Pittsburgh, Pennsylvania, United States
  • Study Site
    Nashville, Tennessee, United States
  • Study Site
    Houston, Texas, United States
  • Study Site
    Richmond, Virginia, United States
08

References and documents

Publications

  • Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW; ICA-17043-05 Investigators. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. PubMed 18192510 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Nov 2003 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2002
First posted
Jul 10, 2002
Start
Feb 2002
Primary completionActual
Nov 2003
CompletionActual
Jan 2004
Results delay requested
Jul 7, 2011
Last update
Jul 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00040677
Lead sponsor
Icagen
First posted
Jul 10, 2002
Start date
Feb 2002
Primary completion
Nov 2003
Completion
Jan 2004
Last update
Jul 18, 2011

Study contacts

Kenneth I Ataga, MD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senicapoc

Start the discussion